NTLA
Overvalued by 157.2% based on the discounted cash flow analysis.
Market cap | $880.46 Million |
---|---|
Enterprise Value | $893.49 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-5.25 |
Beta | 2.33 |
Outstanding Shares | 103,500,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.67 |
---|---|
PEG | -15.16 |
Price to Sales | - |
Price to Book Ratio | 1.29 |
Enterprise Value to Revenue | 20.74 |
Enterprise Value to EBIT | -1.69 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | 0.16 |
Debt to Equity | 0.18 |
No data
No data
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...